News Conference News ACC 2024 Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI Yael L. Maxwell April 06, 2024
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ACC 2022 PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI Todd Neale April 03, 2022
News Conference News ACC 2022 APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study Michael O'Riordan April 03, 2022
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News ACC 2018 SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients Michael O'Riordan March 11, 2018
News Conference News ACC 2017 Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS Michael O'Riordan March 19, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term Michael O'Riordan March 10, 2017